Safety Study of GBS Following Menactra Meningococcal Vaccination

Key facts

Sponsor

Harvard Pilgrim Health Care

Principal Investigator

Richard Platt, MD, MS

Dept. of Ambulatory Care and Prevention, HMS/HPHC

Enrollment

6000000 enrolled

Eligibility

11-21 years · All sexes

Timeline

2005 – 2010

Study locations (6)

• HealthCore, Inc., Wilmington, Delaware, United States
• Kaiser Permanente Center for Health Research Hawaii, Honolulu, Hawaii, United States
• Department of Ambulatory Care and Prevention, Harvard Medical School and Harvard Pilgrim Health Care, Boston, Massachusetts, United States
• i3 Drug Safety, Waltham, Massachusetts, United States
• Aetna, Inc., Blue Bell, Pennsylvania, United States
• Highmark Blue Cross Blue Shield, Pittsburgh, Pennsylvania, United States

Collaborators

Aetna, Inc. · HealthCore, Inc. · Highmark Blue Cross Blue Shield · i3 Drug Safety · Kaiser Permanente

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Functional variant of Guillain-Barré syndrome

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE3NCT07020819
  An Open Label Clinical Study to Evaluate Tanruprubart (Also Commonly Known as ANX005) in Participants With Guillain-Barré Syndrome (FORWARD Study)
  Annexon, Inc.
• RECRUITINGNANCT06996509
  Noninvasive Support for Acute Respiratory Failure in Guillain-Barré Syndrome
  Assiut University
• RECRUITINGNCT06612242
  Early vs. Late Tracheostomy in Patients With Guillain -Barre Syndrome
  Meir Medical Center
• RECRUITINGNANCT06167239
  Ventilator Trigger Sensitivity Adjustment Versus Threshold Inspiratory Muscle Training on Arterial Blood Gases
  Cairo University
• RECRUITINGNCT04829526
  Firm Observational Clinical Unicenter Study on Guillain Barré Syndrome
  University Hospital, Basel, Switzerland

See all trials for Functional variant of Guillain-Barré syndrome →